RecruitingPHASE1, PHASE2NCT03013998

Study of Biomarker-Based Treatment of Acute Myeloid Leukemia

Studying Inherited acute myeloid leukemia

Last synced from ClinicalTrials.gov May 12, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Beat AML, LLC
Principal Investigator: John C Byrd, MD
Beat AML
Intervention: Samalizumab (BAML-16-001-S1)(biological)
Enrollment: 3000 enrolled
Eligibility: 18 years · All sexes
Timeline: 2016 – 2028

Study locations (19)

Mayo Clinic Arizona, Phoenix, Arizona, United States
UCLA Ronald Reagan Medical Center, Los Angeles, California, United States
University of California, San Francisco, San Francisco, California, United States
University of Colorado, Denver, Colorado, United States
University of Florida Health Shands Cancer Hospital, Gainesville, Florida, United States
Mayo Clinic Florida, Jacksonville, Florida, United States
Emory University, Atlanta, Georgia, United States
University of Chicago, Chicago, Illinois, United States
University of Kansas Clinical Research Center, Fairway, Kansas, United States
University of Maryland Medical Center, Baltimore, Maryland, United States
Mayo Clinic Minnesota, Rochester, Minnesota, United States
Memorial Sloan Kettering Cancer Center, New York, New York, United States
UNC Hospitals, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
University of Cincinnati Medical Center, Cincinnati, Ohio, United States
Ohio State University, Columbus, Ohio, United States
+4 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03013998 on ClinicalTrials.gov

Other trials for Inherited acute myeloid leukemia

Additional recruiting or active studies for the same condition.

See all trials for Inherited acute myeloid leukemia →

← Back to all trials